---
title: "Repatha (evolocumab), all indications: Specific populations questions"
description: "Specific populations questions on Repatha (evolocumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Repatha be used during pregnancy? Can Repatha be used while breastfeeding? Is Repatha safe and effective for adults 65 and older? Does Repatha need a dose adjustment for kidney or liver impairment? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/repatha/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Repatha (evolocumab), all indications: Specific populations questions

Manufacturer: Amgen Inc.  
Prescribing information: [Repatha](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf)  
Indication pages: [Cardiovascular event risk reduction](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction)

## Pregnancy and breastfeeding

<a id="repatha-pregnancy"></a>

### Can Repatha be used during pregnancy?

> “Available data from clinical trials and postmarketing reports on REPATHA use in pregnant women are 
> insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse 
> maternal or fetal outcomes. In animal reproduction studies, there were no effects on pregnancy or 
> neonatal/infant development when monkeys were subcutaneously administered evolocumab from 
> organogenesis through parturition at dose exposures up to 12 times the exposure at the maximum 
> recommended human dose of 420 mg every month. In a similar study with another drug in the PCSK9 
> inhibitor antibody class, humoral immune suppression was observed in infant monkeys exposed to that 
> drug in utero at all doses. The exposures where immune suppression occurred in infant monkeys were 
> greater than those expected clinically. No assessment for immune suppression was conducted with 
> evolocumab in infant monkeys. Measurable evolocumab serum concentrations were observed in the 
> infant monkeys at birth at comparable levels to maternal serum, indicating that evolocumab, like other 
> IgG antibodies, crosses the placental barrier. Monoclonal antibodies are transported across the placenta in 
> increasing amounts especially near term; therefore, evolocumab has the potential to be transmitted from 
> the mother to the developing fetus.”

Source: [REPATHA: Prescribing information, page 8, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=8)

<a id="repatha-breastfeeding"></a>

### Can Repatha be used while breastfeeding?

> “There is no information regarding the presence of evolocumab in human milk, the effects on the breastfed 
> infant, or the effects on milk production. Human IgG is present in human milk, but published data suggest 
> that breast milk antibodies do not enter the neonatal and infant circulation in substantial amounts.”

Source: [REPATHA: Prescribing information, page 8, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=8)

> “The development and health benefits of breastfeeding should be considered along with the mother’s 
> clinical need for REPATHA and any potential adverse effects on the breastfed infant from REPATHA or 
> from the underlying maternal condition.”

Source: [REPATHA: Prescribing information, page 9, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=9)

## Specific populations

<a id="repatha-older-adults"></a>

### Is Repatha safe and effective for adults 65 and older?

> “In controlled trials, 11,112 (45%) patients treated with REPATHA were ≥ 65 years old and 2,130 (9%) 
> were ≥ 75 years old. No overall differences in safety or effectiveness were observed between these 
> patients and younger patients, and other reported clinical experience has not identified differences in 
> responses between the elderly and younger patients, but greater sensitivity of some older individuals 
> cannot be ruled out.”

Source: [REPATHA: Prescribing information, page 9, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=9)

<a id="repatha-kidney-liver"></a>

### Does Repatha need a dose adjustment for kidney or liver impairment?

> “No dose adjustment is needed in patients with renal impairment [see Clinical Pharmacology (12.3)].”

Source: [REPATHA: Prescribing information, page 9, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=9)

> “No dose adjustment is needed in patients with mild to moderate hepatic impairment (Child-Pugh A or B). 
> No data are available in patients with severe hepatic impairment [see Clinical Pharmacology (12.3)].”

Source: [REPATHA: Prescribing information, page 9, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=9)

<a id="repatha-overdose"></a>

### What should patients do if they use too much Repatha?

> “If you or your child use more REPATHA than you should, talk to your healthcare provider or pharmacist.”

Source: [REPATHA: Prescribing information, page 29, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=29)

Note: This passage is from the FDA-approved Patient Information printed with the Prescribing Information, which covers adult and pediatric use. The Prescribing Information revised 10/2026 has no Overdosage section.

## Related pages
- [Medical information: Repatha (evolocumab): All indications](https://www.evicenter.com/medical-information/repatha)
- [Indication](https://www.evicenter.com/medical-information/repatha/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/repatha/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/repatha/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/repatha/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/repatha/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/repatha/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/repatha/access-and-coverage)
